INNM.F Stock Overview
A pharmaceutical company, focuses on the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Amplia Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.047 |
| 52 Week High | AU$0.08 |
| 52 Week Low | AU$0.025 |
| Beta | 0.53 |
| 11 Month Change | 18.50% |
| 3 Month Change | -5.20% |
| 1 Year Change | -21.00% |
| 33 Year Change | -72.29% |
| 5 Year Change | -31.20% |
| Change since IPO | -69.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| INNM.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 18.5% | -2.7% | 1.1% |
| 1Y | -21.0% | 6.9% | 22.5% |
Return vs Industry: INNM.F underperformed the US Biotechs industry which returned 10.4% over the past year.
Return vs Market: INNM.F underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| INNM.F volatility | |
|---|---|
| INNM.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: INNM.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine INNM.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Chris Burns | www.ampliatx.com |
Amplia Therapeutics Limited, a pharmaceutical company, focuses on the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline includes AMP945, an inhibitor of FAK that has completed Phase I clinical trial for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases; and AMP886 for treating acute myeloid leukemia and various solid tumors. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018.
Amplia Therapeutics Limited Fundamentals Summary
| INNM.F fundamental statistics | |
|---|---|
| Market cap | US$11.68m |
| Earnings (TTM) | -US$3.03m |
| Revenue (TTM) | US$2.99m |
3.9x
P/S Ratio-3.9x
P/E RatioIs INNM.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INNM.F income statement (TTM) | |
|---|---|
| Revenue | AU$4.45m |
| Cost of Revenue | AU$441.99k |
| Gross Profit | AU$4.01m |
| Other Expenses | AU$8.51m |
| Earnings | -AU$4.50m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | 90.07% |
| Net Profit Margin | -101.14% |
| Debt/Equity Ratio | 13.1% |
How did INNM.F perform over the long term?
See historical performance and comparison